The 3rd Sustainability Report confirms IBSA’s commitment to the well-being of the Person 20 December 2021
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) 2 December 2021
Intervista al Presidente FIT Giorgio Calderari, Falò RSI La 1, giovedì 25 novembre 2021 26 November 2021
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types 19 November 2021
Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR 12 October 2021
Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor 7 October 2021
Linkedin